Efficacy of aldosterone receptor antagonism in heart failure: Potential mechanisms

Current Heart Failure Reports

Volumn 1, Issue 2, 2004, Pages 51-56

  Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aldosterone; Eplerenone; Heart Rate Variability; Primary Aldosteronism; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MAGNESIUM; POTASSIUM; SODIUM; SULFONAMIDE;

BLOOD VESSEL; CONGESTIVE HEART FAILURE; HUMAN; HYPERALDOSTERONISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD VESSELS; CALCIUM; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERALDOSTERONISM; MAGNESIUM; POTASSIUM; SODIUM; SULFONAMIDES;

EID: 26044474573     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-004-0025-4     Document Type: Article

References (47)

1. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. The RALES trial, conducted in more than 1600 patients in 19 countries on five continents, demonstrated the efficacy of spironolactone (in combination with ACE inhibitor and loop diuretic) in patients with symptomatic heart failure. A remarkable 30% reduction in risk for all-cause mortality and cardiovascular-related mortality, including sudden death, was observed. DOI: 10.1056/NEJM199909023411001
2. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321. The EPHESUS trial, conducted in more than 6600 patients with symptomatic heart failure after a recent MI, included 674 centers in 37 countries on three continents and demonstrated the efficacy of eplerenone (in combination with ACE inhibitor, loop diuretic, and â-adrenergic receptor antagonist) in significantly reducing risk for the same end points observed in the RALES trial. DOI: 10.1056/NEJMoa030207
3. Weber KT: Aldosteronism revisited. Perspectives on less well-recognized actions of aldosterone. J Lab Clin Med 2003, 142:71–82. DOI: 10.1016/S0022-2143(03)00062-3
4. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689–1697. DOI: 10.1056/NEJMra000050
5. Armanini D, Witzgall H, Wehling M, et al.: Aldosterone receptors in different types of primary hyperaldosteronism. J Clin Endocrinol Metab 1987, 65:101–104. DOI: 10.1210/jcem-65-1-101
6. Delva P, Pastori C, Degan M, et al.: Intralymphocyte free magnesium in patients with primary aldosteronism: aldosterone and lymphocyte magnesium homeostasis. Hypertension 2000, 35:113–117.
7. Gerling IC, Sun Y, Ahokas RA, et al.: Aldosteronism: an immunostimulatory state precedes the proinflammatory/ fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003, 285:H813-H821.
8. Ahokas RA, Warrington KJ, Gerling IC, et al.: Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res 2003, 93:e124-e135. DOI: 10.1161/01.RES.0000102404.81461.25
9. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700–2706.
10. Sun Y, Zhang J, Lu L, et al.: Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002, 161:1773–1781.
11. Wiles ME, Wagner TL, Weglicki WB: Effect of acute magnesium deficiency (MgD) on aortic endothelial cell (EC) oxidant production. Life Sci 1997, 60:221–236. DOI: 10.1016/S0024-3205(96)00619-4
12. Weglicki WB, Mak IT, Stafford RE, et al.: Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition. Mol Cell Biochem 1994, 130:103–109. DOI: 10.1007/BF01457391
13. Weglicki WB, Dickens BF, Wagner TL, et al.: Immunoregulation by neuropeptides in magnesium deficiency: ex vivo effect of enhanced substance P production on circulating T lymphocytes from magnesium-deficient mice. Magnes Res 1996, 9:3–11.
14. Mak IT, Komarov AM, Wagner TL, et al.: Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am J Physiol 1996, 271:C385-C390.
15. Weglicki WB, Mak IT, Phillips TM: Blockade of cardiac inflammation in Mg2+ deficiency by substance P receptor inhibition. Circ Res 1994, 74:1009–1013.
16. Aukrust P, Ueland T, Müller F, et al.: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998, 97:1136–1143.
17. Damås JK, Gullestad L, Ueland T, et al.: CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 2000, 45:428–436. DOI: 10.1016/S0008-6363(99)00262-X
18. Damås JK, Gullestad L, Aass H, et al.: Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001, 38:187–193. DOI: 10.1016/S0735-1097(01)01335-3
19. Felder RB, Francis J, Zhang ZH, et al.: Heart failure and the brain: new perspectives. Am J Physiol 2003, 284:R259-R276.
20. Anker SD, Chua TP, Ponikowski P, et al.: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997, 96:526–534.
21. Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993, 21:929–933.
22. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594–597.
23. Bauersachs J, Heck M, Fraccarollo D, et al.: Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002, 39:351–358. DOI: 10.1016/S0735-1097(01)01729-6
24. Gomez-Sanchez CE, Zhou MY, Cozza EN, et al.: Aldosterone biosynthesis in the rat brain. Endocrinology 1997, 138:3369–3373. DOI: 10.1210/en.138.8.3369
25. Zhang ZH, Francis J, Weiss RM, Felder RB: The reninangiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol 2002, 283:H423-H433.
26. Francis J, Weiss RM, Wei SG, et al.: Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol 2001, 281:H2241-H2251.
27. Francis J, Weiss RM, Johnson AK, Felder RB: Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. Am J Physiol Regul Integr Comp Physiol 2003, 284:R328-R335.
28. Adamopoulos S, Ponikowski P, Cerquetani E, et al.: Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. Eur Heart J 1995, 16:1380–1386.
29. Furlan R, Guzzetti S, Crivellaro W, et al.: Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation 1990, 81:537–547.
30. Raeder EA, Hohnloser SH, Graboys TB, et al.: Spontaneous variability and circadian distribution of ectopic activity in patients with malignant ventricular arrhythmia. J Am Coll Cardiol 1988, 12:656–661.
31. Nolan J, Batin PD, Andrews R, et al.: Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998, 98:1510–1516.
32. Yee KM, Pringle SD, Struthers AD: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001, 37:1800–1807. DOI: 10.1016/S0735-1097(01)01243-8
33. Barr CS, Lang CC, Hanson J, et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259–1265. DOI: 10.1016/S0002-9149(99)80353-1
34. Kasama S, Toyama T, Kumakura H, et al.: Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002, 43:1279–1285.
35. Takeda Y, Miyamori I, Yoneda T, et al.: Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170–173.
36. Takeda Y, Miyamori I, Yoneda T, et al.: Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996, 81:2797–2800. DOI: 10.1210/jc.81.8.2797
37. Silvestre JS, Robert V, Heymes C, et al.: Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem 1998, 273:4883–4891. DOI: 10.1074/jbc.273.9.4883
38. Hatakeyama H, Miyamori I, Fujita T, et al.: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316–24320.
39. Weber KT: Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 1997, 96:4065–4082.
40. Sun Y, Zhang JQ, Zhang J, Ramires FJ: Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 1998, 30:1559–1569. DOI: 10.1006/jmcc.1998.0721
41. Silvestre JS, Heymes C, Oub’enaïssa A, et al.: Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694–2701.
42. Robert V, Heymes C, Silvestre JS, et al.: Angiotensin AT1 receptor subtype as a cardiac target of aldosterone. Role in aldosterone-salt-induced fibrosis. Hypertension 1999, 33:981–986.
43. Sun Y, Zhang J, Lu L, et al.: Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 2004, 143:41–51. DOI: 10.1016/j.lab.2003.07.004
44. Delcayre C, Silvestre JS, Garnier A, et al.: Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000, 57:1346–1351. DOI: 10.1046/j.1523-1755.2000.00973.x
45. Delyani JA, Robinson EL, Rudolph AE: Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol 2001, 281:H647-H654.
46. Hayashi M, Tsutamoto T, Wada A, et al.: Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001, 38:1375–1382. DOI: 10.1016/S0735-1097(01)01539-X
47. Tsutamoto T, Wada A, Maeda K, et al.: Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:838–844. DOI: 10.1016/S0735-1097(00)00796-8